All News
Race to the top: how high will treatment response rates in RA reach?
We have become accustomed to the 60/40/20% rule for the outcome of ACR 20/50/70 respectively for biologics and targeted synthetic DMARDs.
Read Article
Plotting Future ACR Convergence Meetings (11.24.2023)
In this week's podcast, Dr. Jack Cush reviews the ACR Convergence 2023 meeting and proposes how to best learn at your next large medical meeting.
Read Article
TNFi and RA-ILD – The Pendulum Swings Again
TNF inhibitors revolutionised the treatment of rheumatoid arthritis. While highly effective for the joint manifestations of the disease, a note of caution was sounded regarding the potential for worsening of ILD with these agents. Within this framework, a study by England et al presented at ACR23 was highly relevant.
Read Article
Biologics in RA: Mechanisms of Delivery Over Mechanisms of Action?
Dr. Aurelie Najm discusses abstract 0838 presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/ffMf0R0ces https://t.co/QCAIrUmdoY
Dr. John Cush RheumNow ( View Tweet)
JAKi and TYK2i: What to use and when?
You can see that the JAKi/TYK2i have both approved or potential seropositive and seronegative indications. There are also improvements in PsO for the class and studies in CTDs. So, it is difficult to know which to choose.
Read Article
Rheumatology Roundup - ACR 2023
Drs. Jack Cush and Arthur Kavanaugh discuss highlights and key takeaways from ACR 23.
Read Article
Secukinumab vs. Adalimumab Biosimilar on Radiographic Progression in AxSpA
Dr. Robert Chao (Tysons, VA) discusses Abstract 0522 presented at the 2023 ACR Convergence meeting in San Diego, CA.
https://t.co/UmcbplfGhB https://t.co/R5Lr6Q0qHI
Dr. John Cush RheumNow ( View Tweet)
Reminder of data for dose reduction #bDMARD by Prof Emery #ACR23
Feasible after early remission induction https://t.co/WwiNp8WKDC
Dr Gurdeep S Dulay ( View Tweet)
Thanks #ACR23 for a wonderful meeting ! Presented a really positive phase 2 clinical trial results of Dazukibart, an IFN beta monoclonal antibody in #Myositis (DM) #pfizer
.Strong efficacy with rapid onset. Safe & tolerable monthly IV injection. Looking forward to start Phase 3. https://t.co/580ICHM8Hs
Rohit Aggarwal ( View Tweet)
Large French study on infection risk of PsA biologics
12k pts over 6 years
When compared to Humira, only Enbrel and Stelara had lower infection risk
Concurrent steroid use associated with increased infection 1.85HR
@RheumNow #ACR23 Abs#2566 https://t.co/Os1esuodfl
Robert B Chao, MD ( View Tweet)
Treatment of RA-ILD patients with ABA at any time of the course in the ILD seems to prevent interstitial lung progression. The evolution of FVC and DLCO for 48 months remained stable with ABA therapy. Serrano-Combarro A, Abst#2173 #ACR23 @RheumNow https://t.co/QE61wzKWXi https://t.co/xd3wvMXUlA
Dr. Antoni Chan ( View Tweet)
Continued interest on CAR-T cells in systemic sclerosis!
6 mo f/up data on 3 pts who received CAR-T cell treatment - stable dz overall
Skin findings improved in all 3 pts
Previous finger ulcerations resolved
Lung function stable in 2 pts, improved in 1
@RheumNow #ACR23 Abs#2598
Robert B Chao, MD ( View Tweet)
#ACR23 Abs 2598 show data on 1st 3 CD19 CAR-T treated SSc pts. Tx well tolerated and dz stabilized off tx x 6 months. Promising, but more data needed for further evaluation. https://t.co/RAKhT6Eygn @rheumnow
Dr. Rachel Tate ( View Tweet)
Interesting late breaker!
Telitacicept - recombinant fusion protein targeting BLyS and APRIL for treatment of RA
Phase 3 study - at wk 24, reached ACR20, ACR50, DAS28-ESR, no radiographic progression
No difference in safety profile compared to placebo
@RheumNow #ACR23 #ACRBest https://t.co/bxWPagGixt
Robert B Chao, MD ( View Tweet)
#ACR23 Abstr#2576 Promising therapy in Dermatomyositis. Phase 2 RCT showed rapid improvement in skin, muscle & patient reported outcomes as fast as Week 4 in PF-06823859 (anti-IFN-B) vs PBO. Could be useful to treat in either skin or muscle predominant patients @RheumNow #ACRBest https://t.co/Rj1k1z0Tsz
Md Yuzaiful Md Yusof ( View Tweet)
Window of opportunity for abatacept in RA-ILD. Early treated patients (<6 months vs >2 years) appear to do better in terms of FVC. Abstr#2173 #ACR23 @RheumNow https://t.co/14IsA1KbAk https://t.co/ZbZEwzaOu0
Richard Conway ( View Tweet)
L20 @ #ACR23
New therapy on the horizon for RA pts that failed MTX?
⭐️Telitacicept = recombinant fusion protein targeting & neutralizing BLyS & APRIL
➡️ placebo-controlled, phase III trial, 24w
👉at wk 24, PBO pts switched to drug arm for 24 more wks
➡️ 479 pts w/… https://t.co/94MyC8sdaG https://t.co/x3MUmFJPK6
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Will CAR T Cells also treat RA?
Dr. Jonathan Kay reports on abstract 0424 from #ACR23.
https://t.co/XvNMXAFkWe https://t.co/HVvBLhqe8H
Dr. John Cush RheumNow ( View Tweet)
👨⚖️ The Great Debate: should we use advanced therapies / biologics at disease onset in PMR & GCA? #ACR23
By Dr. Robert Spiera & Dr. Phil Seo @philseo #Vasculitis #PMR #GCA https://t.co/rkcUeEBLeZ
Mithu Maheswaranathan, MD ( View Tweet)
Part 2: Clinical Year in Review #ACR23 https://t.co/Yb8Xh2UKFY
Mithu Maheswaranathan, MD ( View Tweet)